The Prix Galien aims to recognize excellence, novelty, and outstanding contributions in the fields of innovative therapeutics and healthcare solutions that serve humanity at large. The products eligible for the Prix Galien Award in India must be fully approved by the Indian authorities (except for the “IA” Startups category) and demonstrate innovative science, developed through synthetic chemistry or molecular biology. These products should be manufactured to precise specifications, tested in controlled clinical trials, and marketed by life science companies. To be eligible, products must have received marketing approval in the Indian market by December 31 of the previous year, but not more than five years prior to that date, unless the award is for a new and innovative invention, which must have been added within the previous five years.

The committee will award prizes in various categories, including the Best;
- Pharmaceutical Agent (small molecule)
- Biotechnology Product
- Product for Rare and Orphan diseases
- Medical Device or Diagnostic approved in the Indian market within the past five years

Candidates will be selected from all therapeutic categories and evaluated based on their innovation during scientific development, application, and clinical utility, as well as the lessons learnt for the future of biomedical science from their introduction to the clinic. Factors such as market size, company size, development costs, or distribution contingencies will not be considered. The committee reserves the right to not select a winner in a particular year. Additionally, the Prix Galien may recognize actors in the healthcare ecosystem such as startups, incubators/accelerators, and digital health initiatives.

All candidates must apply online through the Galien Foundation website. Also, the nominations byExperts can be online. Moreover, at the discretion of the committee, the Prix Galien may award a special Pro Bono Humanum award to an individual, company, academic institution, or non-governmental agency that has contributed to improving the human condition through the application of biopharmaceutical science, particularly in developing for underserved populations worldwide. The committee plans to introduce other new awards aligned with the mission of the Prix Galien, and these awards will be judged by the committee members.

The awards committee will consist of up to 15 individuals and an honorary member. The committee is supported by sub-committees. Committee members generally serve for one or a maximum of two three-year terms, with staggered membership durations. Members are distinguished individuals from the scientific and research communities, primarily from the local region, with at least one international member. In addition to outstanding academic credentials, committee members should possess expertise and understanding of human therapeutics and familiarity with healthcare issues. The committee will select a Chair who will serve for two years. Nominations for the committee can be made by current and former committee members, the academic and research communities, and scientific divisions of companies engaged in the development of human therapeutics.

The decisions of the independent committee regarding the selection of award winners will be final and made solely by the committee. The deliberations of respective Committees will be conducted privately without any influence from the Galien Foundation Board, member organizations, or other sponsors.

Important precision:
The Prix Galien India, conceived in collaboration with the GM Modi Foundation, champions groundbreaking therapeutics and healthcare solutions that serve humanity at large. The products eligible for the Prix Galien in India must be fully approved by the Indian authorities (except for the “IA” Startups category) and demonstrate innovative science, developed through synthetic chemistry or molecular biology. These products should be manufactured to precise specifications, tested in controlled clinical trials, and marketed by life science companies. To be eligible, products must have received marketing approval in the Indian market by December 31 of the previous year, but not more than five years prior to that date, unless the award is for a new and innovative invention, which must have been added within the previous five years.

Objective and Scope:
1) **Partnership and Purpose:** The Prix Galien India awards, forged in alliance with the GM Modi Foundation, stand as a testament to Scientific and Technological Excellence across the broad domains of Health and Wellness, notably Pharmaceuticals and Nutraceuticals.
2) **Eligibility and Inclusivity:** Indian Scientists from diverse arenas - be it Academia, Industry, Foundations, Not-for-Profit Organizations, or budding Startups - are encouraged to vie for this recognition.
3) **Focus on Indigenous Innovations:** While the award gives credence to both individual or collective efforts, the spotlight is undeniably on innovations germinated and nurtured within Indian soil. International collaborations, if any, will serve as value additions.
4) **Best Biotech Product:** This category seeks products that have made their market debut in the past half-decade. They should echo societal imperatives, highlighting innovation, affordability, and accessibility.
5) **For the Rare and the Overlooked:** Entrants in this segment should cater to early detection, diagnosis, and therapeutics for rare and genetic disorders. Diagnostic tools, early screenings based on genomic markers, or enzyme therapies, and stage-wise drug developments all fall under this umbrella.
6) **Championing Entrepreneurial Spirit:** The award also shines a light on the best in the Biotech/ Healthcare start-up ecosystem, recognizing trailblazing start-ups, proactive incubators, and accelerators.
7) **Nomination Mechanism:** Prospective candidates can either initiate their application or be endorsed by revered entities within the scientific community. This encompasses Experts, Organizations, Academies, and prominent Industry bodies.

Nomination Mechanism:
- Prospective candidates can either initiate their application or be endorsed by revered entities within the scientific community.
- This encompasses Experts, Organizations, Academies, and prominent Industry bodies.